nach oben

Endocrine

Erschienen in:

11.04.2016 | Mini Review

Non-functioning pituitary adenomas: growth and aggressiveness

verfasst von: Kristin Astrid Øystese, Johan Arild Evang, Jens Bollerslev

Erschienen in: Endocrine | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Pituitary adenomas (PAs) are common, comprising approximately one third of all intracranial tumors. Non-functioning pituitary adenomas (NFPAs) are the most common PAs. Although usually benign, the NFPAs represent therapeutic challenges because of their location close to the optic chiasm and nerves, and the proximity to the pituitary gland. The therapeutic alternatives are surgery and radiation. To date there is no effective medical treatment. NFPAs are classified according to different modalities, but there are no reliable marker of aggressiveness to guide the clinician in monitoring the patient. More information on growth patterns with constituent biological markers are needed to tailor the care of this patient group. Studies characterizing the membrane receptors of NFPAs have shown promising results, which may give rise to the development of medical treatment.

E.D. Aflorei, M. Korbonits, Epidemiology and etiopathogenesis of pituitary adenomas. J. Neurooncol. 117(3), 379–394 (2014). doi:10.1007/s11060-013-1354-5 CrossRefPubMed

G. Vargas, B. Gonzalez, C. Ramirez, A. Ferreira, E. Espinosa, V. Mendoza, G. Guinto, B. Lopez-Felix, E. Zepeda, M. Mercado, Clinical characteristics and treatment outcome of 485 patients with nonfunctioning pituitary macroadenomas. Int. J. Endocrinol. 2015, 756069 (2015). doi:10.1155/2015/756069 CrossRefPubMedPubMedCentral

O. Cooper, S. Melmed, Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best practice & research. Clinical. Endocrinol. Metab 26(4), 447–460 (2012). doi:10.1016/j.beem.2012.01.002

G. Carosi, E. Malchiodi, E. Ferrante, E. Sala, E. Verrua, E. Profka, C. Giavoli, M. Filopanti, P. Beck-Peccoz, A. Spada, G. Mantovani, Hypothalamic-pituitary axis in non-functioning pituitary adenomas: focus on the prevalence of isolated central hypoadrenalism. Neuroendocrinology 102(4), 267–273 (2015). doi:10.1159/000430815 CrossRefPubMed

O. Vierimaa, M. Georgitsi, R. Lehtonen, P. Vahteristo, A. Kokko, A. Raitila, K. Tuppurainen, T.M. Ebeling, P.I. Salmela, R. Paschke, S. Gundogdu, E. De Menis, M.J. Makinen, V. Launonen, A. Karhu, L.A. Aaltonen, Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312(5777), 1228–1230 (2006). doi:10.1126/science.1126100 CrossRefPubMed

C. Esteves, C. Neves, L. Augusto, J. Menezes, J. Pereira, I. Bernardes, J. Fonseca, D. Carvalho, Pituitary incidentalomas: analysis of a neuroradiological cohort. Pituitary 18(6), 777–781 (2015). doi:10.1007/s11102-015-0652-7 CrossRefPubMed

T.T. Agustsson, T. Baldvinsdottir, J.G. Jonasson, E. Olafsdottir, V. Steinthorsdottir, G. Sigurdsson, A.V. Thorsson, P.V. Carroll, M. Korbonits, R. Benediktsson, The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur. J. Endocrinol. 173(5), 655–664 (2015). doi:10.1530/eje-15-0189 CrossRefPubMed

A. Tjornstrand, K. Gunnarsson, M. Evert, E. Holmberg, O. Ragnarsson, T. Rosen, Filipsson Nystrom, H.: the incidence rate of pituitary adenomas in western Sweden for the period 2001–2011. Eur. J. Endocrinol. 171(4), 519–526 (2014). doi:10.1530/eje-14-0144 CrossRefPubMed

A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf) 72(3), 377–382 (2010). doi:10.1111/j.1365-2265.2009.03667.x CrossRef

10.

A.F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M.A. Tichomirowa, A. Beckers, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91(12), 4769–4775 (2006). doi:10.1210/jc.2006-1668 CrossRefPubMed

11.

A. Di Ieva, F. Rotondo, L.V. Syro, M.D. Cusimano, K. Kovacs, Aggressive pituitary adenomas–diagnosis and emerging treatments. Nat. Rev. Endocrinol. 10(7), 423–435 (2014). doi:10.1038/nrendo.2014.64 CrossRefPubMed

12.

S.E. Mayson, P.J. Snyder, Silent pituitary adenomas. Endocrinol. Metab. Clin. North Am. 44(1), 79–87 (2015). doi:10.1016/j.ecl.2014.11.001 CrossRefPubMed

13.

H. Nishioka, N. Inoshita, O. Mete, S.L. Asa, K. Hayashi, A. Takeshita, N. Fukuhara, M. Yamaguchi-Okada, Y. Takeuchi, S. Yamada, The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr. Pathol. 26(4), 349–355 (2015). doi:10.1007/s12022-015-9398-z CrossRefPubMed

14.

R. DeLellis, P. Heitz, World Health Organization Classification of Tumours: Tumours of Endocrine Organs. IARC PRess, Lyon (2004)

15.

C. Ramirez, S. Cheng, G. Vargas, S.L. Asa, S. Ezzat, B. Gonzalez, L. Cabrera, G. Guinto, M. Mercado, Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J. Clin. Endocrinol. Metab. 97(5), 1745–1751 (2012). doi:10.1210/jc.2011-3163 CrossRefPubMed

16.

A. Righi, P. Agati, A. Sisto, G. Frank, M. Faustini-Fustini, R. Agati, D. Mazzatenta, A. Farnedi, F. Menetti, G. Marucci, M.P. Foschini, A classification tree approach for pituitary adenomas. Hum. Pathol. 43(10), 1627–1637 (2012). doi:10.1016/j.humpath.2011.12.003 CrossRefPubMed

17.

J. Trouillas, P. Roy, N. Sturm, E. Dantony, C. Cortet-Rudelli, G. Viennet, J.F. Bonneville, R. Assaker, C. Auger, T. Brue, A. Cornelius, H. Dufour, E. Jouanneau, P. Francois, F. Galland, F. Mougel, F. Chapuis, L. Villeneuve, C.A. Maurage, D. Figarella-Branger, G. Raverot, A. Barlier, M. Bernier, F. Bonnet, F. Borson-Chazot, G. Brassier, S. Caulet-Maugendre, O. Chabre, P. Chanson, J.F. Cottier, B. Delemer, E. Delgrange, L. Di Tommaso, S. Eimer, S. Gaillard, M. Jan, J.J. Girard, V. Lapras, H. Loiseau, J.G. Passagia, M. Patey, A. Penfornis, J.Y. Poirier, G. Perrin, A. Tabarin, A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 126(1), 123–135 (2013). doi:10.1007/s00401-013-1084-y CrossRefPubMed

18.

M. Guarino, B. Rubino, G. Ballabio, The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39(3), 305–318 (2007). doi:10.1080/00313020701329914 CrossRefPubMed

19.

S.L. Fougner, T. Lekva, O.C. Borota, J.K. Hald, J. Bollerslev, J.P. Berg, The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J. Clin. Endocrinol. Metab. 95(5), 2334–2342 (2010). doi:10.1210/jc.2009-2197 CrossRefPubMed

20.

T. Lekva, J.P. Berg, S.L. Fougner, O.K. Olstad, T. Ueland, J. Bollerslev, Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly. J. Clin. Endocrinol. Metab. 97(8), E1506–E1514 (2012). doi:10.1210/jc.2012-1760 CrossRefPubMed

21.

J.A. Evang, J.P. Berg, O. Casar-Borota, T. Lekva, M.K. Kringen, J. Ramm-Pettersen, J. Bollerslev, Reduced levels of E-cadherin correlate with progression of corticotroph pituitary tumours. Clin. Endocrinol. (Oxf) 75(6), 811–818 (2011). doi:10.1111/j.1365-2265.2011.04109.x CrossRef

22.

H. Halvorsen, J. Ramm-Pettersen, R. Josefsen, P. Ronning, S. Reinlie, T. Meling, J. Berg-Johnsen, J. Bollerslev, E. Helseth, Surgical complications after transsphenoidal microscopic and endoscopic surgery for pituitary adenoma: a consecutive series of 506 procedures. Acta Neurochir. (Wien) 156(3), 441–449 (2014). doi:10.1007/s00701-013-1959-7 CrossRef

23.

J. Honegger, U. Ernemann, T. Psaras, B. Will, Objective criteria for successful transsphenoidal removal of suprasellar nonfunctioning pituitary adenomas. A prospective study. Acta Neurochir. 149(1), 21–29 (2007). doi:10.1007/s00701-006-1044-6 CrossRefPubMed

24.

R. Reddy, S. Cudlip, J.V. Byrne, N. Karavitaki, J.A. Wass, Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma? Eur. J. Endocrinol. 165(5), 739–744 (2011). doi:10.1530/eje-11-0566 CrossRefPubMed

25.

A. Colao, G. Cerbone, P. Cappabianca, D. Ferone, A. Alfieri, F. Di Salle, A. Faggiano, B. Merola, E. de Divitiis, G. Lombardi, Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas. J. Endocrinol. Invest. 21(5), 284–290 (1998). doi:10.1007/bf03350330 CrossRefPubMed

26.

D. Ding, C.P. Yen, R.M. Starke, C.C. Lee, J.P. Sheehan, Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy. J. Neurooncol. 119(3), 513–529 (2014). doi:10.1007/s11060-014-1501-7 CrossRefPubMed

27.

G. Ntali, N. Karavitaki, Efficacy and complications of pituitary irradiation. Endocrinol. Metab. Clin. North Am. 44(1), 117–126 (2015). doi:10.1016/j.ecl.2014.10.009 CrossRefPubMed

28.

N.C. van Varsseveld, C.C. van Bunderen, D.H. Ubachs, A.A. Franken, H.P. Koppeschaar, A.J. van der Lely, M.L. Drent, Cerebrovascular events, secondary intracranial tumors, and mortality after radiotherapy for nonfunctioning pituitary adenomas: a subanalysis from the dutch national registry of growth hormone treatment in adults. J. Clin. Endocrinol. Metab. 100(3), 1104–1112 (2015). doi:10.1210/jc.2014-3697 CrossRefPubMed

29.

D. Ding, R.M. Starke, J.P. Sheehan, Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy. J. Neurooncol. 117(3), 445–457 (2014). doi:10.1007/s11060-013-1262-8 CrossRefPubMed

30.

E. Chatzellis, K.I. Alexandraki, I.I. Androulakis, G. Kaltsas, Aggressive pituitary tumors. Neuroendocrinology 101(2), 87–104 (2015). doi:10.1159/000371806 CrossRefPubMed

31.

S.E. Combs, K. Kessel, D. Habermehl, T. Haberer, O. Jakel, J. Debus, Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base. Acta Oncol. 52(7), 1504–1509 (2013). doi:10.3109/0284186x.2013.818255 CrossRefPubMed

32.

D.A. Wattson, S.K. Tanguturi, D.Y. Spiegel, A. Niemierko, B.M. Biller, L.B. Nachtigall, M.R. Bussiere, B. Swearingen, P.H. Chapman, J.S. Loeffler, H.A. Shih, Outcomes of proton therapy for patients with functional pituitary adenomas. Int. J. Radiat. Oncol. Biol. Phys. 90(3), 532–539 (2014). doi:10.1016/j.ijrobp.2014.06.068 CrossRefPubMed

33.

Vieira Neto, L. Wildemberg, L.E. Moraes, A.B. Colli, L.M. Kasuki, N.V. Marques, E.L. Gasparetto, M. Takiya, C.M. Gadelha, Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy. Clin. Endocrinol. (Oxf) 82(5), 739–746 (2015). doi:10.1111/cen.12684 CrossRef

34.

Y. Greenman, N. Stern, Optimal management of non-functioning pituitary adenomas. Endocrine 50(1), 51–55 (2015). doi:10.1007/s12020-015-0685-8 CrossRefPubMed

35.

St. Olavs Hospital; Norwegian University of Science Technology: Dopamine agonist treatment of non-functioning pituitary adenomas (NFPAs)—a randomized controlled trial. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US)

36.

S.L. Fougner, O.C. Borota, J.P. Berg, J.K. Hald, J. Ramm-Pettersen, J. Bollerslev, The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin. Endocrinol. (Oxf) 68(3), 458–465 (2008). doi:10.1111/j.1365-2265.2007.03065.x CrossRef

37.

C. Bruns, I. Lewis, U. Briner, G. Meno-Tetang, G. Weckbecker, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146(5), 707–716 (2002)CrossRefPubMed

38.

D. Iacovazzo, E. Carlsen, F. Lugli, S. Chiloiro, S. Piacentini, A. Bianchi, A. Giampietro, M. Mormando, A.J. Clear, F. Doglietto, C. Anile, G. Maira, L. Lauriola, G. Rindi, F. Roncaroli, A. Pontecorvi, M. Korbonits, L. De Marinis, Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur. J. Endocrinol. 174(2), 241–250 (2016). doi:10.1530/eje-15-0832 CrossRefPubMed

39.

H. Nishioka, K. Tamura, H. Iida, M. Kutsukake, A. Endo, Y. Ikeda, J. Haraoka, Co-expression of somatostatin receptor subtypes and estrogen receptor-alpha mRNAs by non-functioning pituitary adenomas in young patients. Mol. Cell. Endocrinol. 331(1), 73–78 (2011). doi:10.1016/j.mce.2010.08.011 CrossRefPubMed

40.

G.F. Taboada, R.M. Luque, W. Bastos, R.F. Guimaraes, J.B. Marcondes, L.M. Chimelli, R. Fontes, P.J. Mata, P.N. Filho, D.P. Carvalho, R.D. Kineman, M.R. Gadelha, Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur. J. Endocrinol. 156(1), 65–74 (2007). doi:10.1530/eje.1.02313 CrossRefPubMed

41.

Vieria Neto, L., Wildemberg, L.E., Colli, L.M., Kasuki, L., Marques, N.V., Moraes, A.B., Gasparetto, E.L., Takiya, C.M., Castro, M., Gadelha, M.R.: zAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas. PLoS ONE 8(10), e77406 (2013). doi:10.1371/journal.pone.0077406 CrossRef

42.

M. Gasperi, L. Petrini, R. Pilosu, M. Nardi, A. Marcello, F. Mastio, L. Bartalena, E. Martino, Octreotide treatment does not affect the size of most non-functioning pituitary adenomas. J. Endocrinol. Invest. 16(7), 541–543 (1993). doi:10.1007/bf03348901 CrossRefPubMed

43.

A. Fusco, A. Giampietro, A. Bianchi, V. Cimino, F. Lugli, S. Piacentini, M. Lorusso, A. Tofani, G. Perotti, L. Lauriola, C. Anile, G. Maira, A. Pontecorvi, L. De Marinis, Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary 15(4), 571–578 (2012). doi:10.1007/s11102-011-0370-8 CrossRefPubMed

44.

M. Lee, A. Lupp, N. Mendoza, N. Martin, R. Beschorner, J. Honegger, J. Schlegel, T. Shively, E. Pulz, S. Schulz, F. Roncaroli, N.S. Pellegata, SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocr. Relat. Cancer 22(1), 111–119 (2015). doi:10.1530/erc-14-0472 CrossRefPubMed

45.

Novartis, P., Novartis: Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. In. Bethesda (MD): National Library of Medicine (US) (2016)

46.

D. Bengtsson, H.D. Schroder, M. Andersen, D. Maiter, K. Berinder, Feldt Rasmussen, U., Rasmussen, A.K., Johannsson, G., Hoybye, C., van der Lely, A.J., Petersson, M., Ragnarsson, O., Burman, P.: long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J. Clin. Endocrinol. Metabo. 100(4), 1689–1698 (2015). doi:10.1210/jc.2014-4350 CrossRef

47.

G. Raverot, F. Castinetti, E. Jouanneau, I. Morange, D. Figarella-Branger, H. Dufour, J. Trouillas, T. Brue, Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin. Endocrinol. (Oxf) 76(6), 769–775 (2012). doi:10.1111/j.1365-2265.2012.04381.x CrossRef

48.

G. Raverot, P. Burman, A. McCormack, S. Petersenn, V. Popovic-Brkic, J. Trouillas, ESE Survey on Aggressive Pituitary Tumors. http://www.ese-hormones.org/professional/

49.

Y. Chen, C.D. Wang, Z.P. Su, Y.X. Chen, L. Cai, Q.C. Zhuge, Z.B. Wu, Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96(4), 333–342 (2012). doi:10.1159/000339823 CrossRefPubMed

50.

E. Monsalves, S. Larjani, B. Loyola Godoy, K. Juraschka, F. Carvalho, W. Kucharczyk, A. Kulkarni, O. Mete, F. Gentili, S. Ezzat, G. Zadeh, Growth patterns of pituitary adenomas and histopathological correlates. J. Clin. Endocrinol. Metab. 99(4), 1330–1338 (2014). doi:10.1210/jc.2013-3054 CrossRefPubMed

51.

C. Cortet-Rudelli, J.F. Bonneville, F. Borson-Chazot, L. Clavier, B. Coche Dequeant, R. Desailloud, D. Maiter, V. Rohmer, J.L. Sadoul, E. Sonnet, P. Toussaint, P. Chanson, Post-surgical management of non-functioning pituitary adenoma. Ann Endocrinol (Paris) 76(3), 228–238 (2015). doi:10.1016/j.ando.2015.04.003 CrossRef

52.

H.M. Kistka, R.A. Kasl, A. Nayeri, A.L. Utz, K.D. Weaver, L.B. Chambless, Imaging of resected nonfunctioning pituitary adenomas: the cost of surveillance. J. Neurol. Surg. 76(5), 344–350 (2015). doi:10.1055/s-0035-1549307 CrossRef

53.

P.U. Freda, A.M. Beckers, L. Katznelson, M.E. Molitch, V.M. Montori, K.D. Post, M.L. Vance, Pituitary incidentaloma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(4), 894–904 (2011). doi:10.1210/jc.2010-1048 CrossRefPubMed

54.

G. Soto-Ares, C. Cortet-Rudelli, R. Assaker, A. Boulinguez, C. Dubest, D. Dewailly, J.P. Pruvo, MRI protocol technique in the optimal therapeutic strategy of non-functioning pituitary adenomas. Eur. J. Endocrinol. 146(2), 179–186 (2002)CrossRefPubMed

55.

E.P. O’Sullivan, C. Woods, N. Glynn, L.A. Behan, R. Crowley, P. O’Kelly, D. Smith, C.J. Thompson, A. Agha, The natural history of surgically treated but radiotherapy-naive nonfunctioning pituitary adenomas. Clin. Endocrinol. (Oxf) 71(5), 709–714 (2009). doi:10.1111/j.1365-2265.2009.03583.x CrossRef

56.

N. Lenders, S. Ikeuchi, A.W. Russell, K.K. Ho, J.B. Prins, W.J. Inder, Longitudinal evaluation of the natural history of conservatively managed non-functioning pituitary adenomas. Clin. Endocrinol. (Oxf) (2015). doi:10.1111/cen.12879

57.

Y. Greenman, G. Ouaknine, I. Veshchev, G. Reider II, Y. Segev, N. Stern, Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin. Endocrinol. (Oxf) 58(6), 763–769 (2003)CrossRef

58.

M. Losa, P. Mortini, R. Barzaghi, P. Ribotto, M.R. Terreni, S.B. Marzoli, S. Pieralli, M. Giovanelli, Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J. Neurosurg. 108(3), 525–532 (2008). doi:10.3171/jns/2008/108/3/0525 CrossRefPubMed

59.

E.F. Chang, G. Zada, S. Kim, K.R. Lamborn, A. Quinones-Hinojosa, J.B. Tyrrell, C.B. Wilson, S. Kunwar, Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J. Neurosurg. 108(4), 736–745 (2008). doi:10.3171/jns/2008/108/4/0736 CrossRefPubMed

60.

F. Roelfsema, N.R. Biermasz, A.M. Pereira, Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15(1), 71–83 (2012). doi:10.1007/s11102-011-0347-7 CrossRefPubMed

61.

J. Honegger, S. Zimmermann, T. Psaras, M. Petrick, M. Mittelbronn, U. Ernemann, M. Reincke, K. Dietz, Growth modelling of non-functioning pituitary adenomas in patients referred for surgery. Eur. J. Endocrinol. 158(3), 287–294 (2008). doi:10.1530/eje-07-0502 CrossRefPubMed

62.

S. Yamada, K. Ohyama, M. Taguchi, A. Takeshita, K. Morita, K. Takano, T. Sano, A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61(3), 580–584 (2007). doi:10.1227/01.neu.0000290906.53685.79 CrossRefPubMed

63.

J.A. Balogun, E. Monsalves, K. Juraschka, K. Parvez, W. Kucharczyk, O. Mete, F. Gentili, G. Zadeh, Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics. Endocr. Pathol. 26(1), 63–70 (2015). doi:10.1007/s12022-014-9347-2 CrossRefPubMed

64.

S. Brochier, F. Galland, M. Kujas, F. Parker, S. Gaillard, C. Raftopoulos, J. Young, O. Alexopoulou, D. Maiter, P. Chanson, Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur. J. Endocrinol. 163(2), 193–200 (2010). doi:10.1530/eje-10-0255 CrossRefPubMed

Titel: Non-functioning pituitary adenomas: growth and aggressiveness
verfasst von: Kristin Astrid Øystese
Johan Arild Evang
Jens Bollerslev
Publikationsdatum: 11.04.2016
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2016
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-016-0940-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Non-functioning pituitary adenomas: growth and aggressiveness

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Blood glucose fluctuation accelerates renal injury involved to inhibit the AKT signaling pathway in diabetic rats

Erratum to: The treatment with pasireotide in Cushing’s disease: effects of long–term treatment on tumor mass in the experience of a single center

Evaluation of the glucocorticoid, mineralocorticoid, and adrenal androgen secretion dynamics in a large cohort of patients aged 6–18 years with transfusion-dependent β-thalassemia major, with an emphasis on the impact of cardiac iron load

Management of hereditary medullary thyroid carcinoma

Bone resorption following weight loss surgery is associated with treatment procedure and changes in secreted Wnt antagonists

Lack of significant association between type 2 diabetes mellitus with longitudinal change in diurnal salivary cortisol: the multiethnic study of atherosclerosis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin